tetano
Editor, Senior Moderator
Nature
. 2020 Jul 30.
doi: 10.1038/s41586-020-2608-y. Online ahead of print.
ChAdOx1 nCoV-19 vaccine prevents SARS-CoV-2 pneumonia in rhesus macaques
Neeltje van Doremalen[SUP] 1 [/SUP], Teresa Lambe[SUP] 2 [/SUP], Alexandra Spencer[SUP] 2 [/SUP], Sandra Belij-Rammerstorfer[SUP] 2 [/SUP], Jyothi N Purushotham[SUP] 1 2 [/SUP], Julia R Port[SUP] 1 [/SUP], Victoria A Avanzato[SUP] 1 [/SUP], Trenton Bushmaker[SUP] 1 [/SUP], Amy Flaxman[SUP] 2 [/SUP], Marta Ulaszewska[SUP] 2 [/SUP], Friederike Feldmann[SUP] 3 [/SUP], Elizabeth R Allen[SUP] 2 [/SUP], Hannah Sharpe[SUP] 2 [/SUP], Jonathan Schulz[SUP] 1 [/SUP], Myndi Holbrook[SUP] 1 [/SUP], Atsushi Okumura[SUP] 1 [/SUP], Kimberly Meade-White[SUP] 1 [/SUP], Lizzette P?rez-P?rez[SUP] 1 [/SUP], Nick J Edwards[SUP] 2 [/SUP], Daniel Wright[SUP] 2 [/SUP], Cameron Bissett[SUP] 2 [/SUP], Ciaran Gilbride[SUP] 2 [/SUP], Brandi N Williamson[SUP] 1 [/SUP], Rebecca Rosenke[SUP] 3 [/SUP], Dan Long[SUP] 3 [/SUP], Alka Ishwarbhai[SUP] 2 [/SUP], Reshma Kailath[SUP] 2 [/SUP], Louisa Rose[SUP] 2 [/SUP], Susan Morris[SUP] 2 [/SUP], Claire Powers[SUP] 2 [/SUP], Jamie Lovaglio[SUP] 3 [/SUP], Patrick W Hanley[SUP] 3 [/SUP], Dana Scott[SUP] 3 [/SUP], Greg Saturday[SUP] 3 [/SUP], Emmie de Wit[SUP] 1 [/SUP], Sarah C Gilbert[SUP] 4 [/SUP], Vincent J Munster[SUP] 5 [/SUP]
Affiliations
Abstract
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) emerged in December 2019[SUP]1,2[/SUP] and is responsible for the COVID-19 pandemic[SUP]3[/SUP]. Vaccines are an essential countermeasure urgently needed to control the pandemic[SUP]4[/SUP]. Here, we show that the adenovirus-vectored vaccine ChAdOx1 nCoV-19, encoding the spike protein of SARS-CoV-2, is immunogenic in mice, eliciting a robust humoral and cell-mediated response. This response was predominantly Th1, as demonstrated by IgG subclass and cytokine expression profiling. Vaccination with ChAdOx1 nCoV-19 (prime-only and prime-boost regimen) induced a balanced Th1/Th2 humoral and cellular immune response in rhesus macaques. We observed a significantly reduced viral load in bronchoalveolar lavage fluid and lower respiratory tract tissue of vaccinated rhesus macaques challenged with SARS-CoV-2 compared with control animals, and no pneumonia was observed in vaccinated animals. However, there was no difference in nasal shedding between vaccinated and control animals. Importantly, no evidence of immune-enhanced disease following viral challenge in vaccinated animals was observed. Safety, immunogenicity and efficacy of ChAdOx1 nCoV-19 against symptomatic PCR-positive COVID-19 disease will now be assessed in randomised controlled human clinical trials.
. 2020 Jul 30.
doi: 10.1038/s41586-020-2608-y. Online ahead of print.
ChAdOx1 nCoV-19 vaccine prevents SARS-CoV-2 pneumonia in rhesus macaques
Neeltje van Doremalen[SUP] 1 [/SUP], Teresa Lambe[SUP] 2 [/SUP], Alexandra Spencer[SUP] 2 [/SUP], Sandra Belij-Rammerstorfer[SUP] 2 [/SUP], Jyothi N Purushotham[SUP] 1 2 [/SUP], Julia R Port[SUP] 1 [/SUP], Victoria A Avanzato[SUP] 1 [/SUP], Trenton Bushmaker[SUP] 1 [/SUP], Amy Flaxman[SUP] 2 [/SUP], Marta Ulaszewska[SUP] 2 [/SUP], Friederike Feldmann[SUP] 3 [/SUP], Elizabeth R Allen[SUP] 2 [/SUP], Hannah Sharpe[SUP] 2 [/SUP], Jonathan Schulz[SUP] 1 [/SUP], Myndi Holbrook[SUP] 1 [/SUP], Atsushi Okumura[SUP] 1 [/SUP], Kimberly Meade-White[SUP] 1 [/SUP], Lizzette P?rez-P?rez[SUP] 1 [/SUP], Nick J Edwards[SUP] 2 [/SUP], Daniel Wright[SUP] 2 [/SUP], Cameron Bissett[SUP] 2 [/SUP], Ciaran Gilbride[SUP] 2 [/SUP], Brandi N Williamson[SUP] 1 [/SUP], Rebecca Rosenke[SUP] 3 [/SUP], Dan Long[SUP] 3 [/SUP], Alka Ishwarbhai[SUP] 2 [/SUP], Reshma Kailath[SUP] 2 [/SUP], Louisa Rose[SUP] 2 [/SUP], Susan Morris[SUP] 2 [/SUP], Claire Powers[SUP] 2 [/SUP], Jamie Lovaglio[SUP] 3 [/SUP], Patrick W Hanley[SUP] 3 [/SUP], Dana Scott[SUP] 3 [/SUP], Greg Saturday[SUP] 3 [/SUP], Emmie de Wit[SUP] 1 [/SUP], Sarah C Gilbert[SUP] 4 [/SUP], Vincent J Munster[SUP] 5 [/SUP]
Affiliations
- PMID: 32731258
- DOI: 10.1038/s41586-020-2608-y
Abstract
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) emerged in December 2019[SUP]1,2[/SUP] and is responsible for the COVID-19 pandemic[SUP]3[/SUP]. Vaccines are an essential countermeasure urgently needed to control the pandemic[SUP]4[/SUP]. Here, we show that the adenovirus-vectored vaccine ChAdOx1 nCoV-19, encoding the spike protein of SARS-CoV-2, is immunogenic in mice, eliciting a robust humoral and cell-mediated response. This response was predominantly Th1, as demonstrated by IgG subclass and cytokine expression profiling. Vaccination with ChAdOx1 nCoV-19 (prime-only and prime-boost regimen) induced a balanced Th1/Th2 humoral and cellular immune response in rhesus macaques. We observed a significantly reduced viral load in bronchoalveolar lavage fluid and lower respiratory tract tissue of vaccinated rhesus macaques challenged with SARS-CoV-2 compared with control animals, and no pneumonia was observed in vaccinated animals. However, there was no difference in nasal shedding between vaccinated and control animals. Importantly, no evidence of immune-enhanced disease following viral challenge in vaccinated animals was observed. Safety, immunogenicity and efficacy of ChAdOx1 nCoV-19 against symptomatic PCR-positive COVID-19 disease will now be assessed in randomised controlled human clinical trials.